<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518568</url>
  </required_header>
  <id_info>
    <org_study_id>V00355 CP 1 02</org_study_id>
    <secondary_id>2015-000544-42</secondary_id>
    <nct_id>NCT02518568</nct_id>
  </id_info>
  <brief_title>Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia</brief_title>
  <official_title>Study of the Pharmacokinetics of Serum Iron After a Single Oral Administration of Ferrous Sulphate Supplement Synthetic Formula in Women With Iron Deficiency Anaemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the pharmacokinetics of serum iron after a single
      oral administration of 160 mg (2 tablets of 80 mg) V0355 in women with iron deficiency
      anaemia.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma concentration (Cmax)</measure>
    <time_frame>up to 24 hours after oral administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Concentration (Tmax)</measure>
    <time_frame>up to 24 hours after oral administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the iron plasma concentration curve (AUC)</measure>
    <time_frame>up to 24 hours after oral administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of single administration</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>Tolerability by evaluating the number of subjects with emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0355</intervention_name>
    <description>Oral administration (2 tablets)</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18-45 years inclusive with iron deficiency anaemia

          -  haemoglobin level between 85 g/L and 105 g/L

          -  serum ferritin level &lt; 15 Âµg/L

          -  D14 +/- 7 days of the menstruation cycle on the day of pharmacokinetic evaluation

        Exclusion Criteria:

          -  Anaemia related to other causes than iron deficiency and particularly inflammatory
             anaemia, anaemia due to marrow failure, haemopathy, haemoglobinopathies (sickle cell
             disease, thalassemia), haemolytic anaemia, anaemia due to acute haemorrhage, or
             anaemia related to chronic renal failure,

          -  Haemochromatosis or iron overload of secondary origin (blood transfusion),

          -  Long term treatment known to modify iron absorption,

          -  Gastro duodenal ulcer,

          -  Inflammatory bowel disease or any digestive disease which could modify iron
             absorption,

          -  Serious or progressive disease (cardiac, pulmonary, hepatic, renal, haematological,
             malignancy, autoimmune disease, infectious disease or neuropsychiatric disorders),

          -  Surgery undergone within 1 month prior to selection visit or a surgery planned during
             the study realization.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

